We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Spinnaker Opportunities Plc | LSE:SOP | London | Ordinary Share | GB00BYQCS703 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.65 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2022 to May 2024
TIDMKNB
RNS Number : 9997U
Kanabo Group PLC
31 March 2023
31 March 2023
Kanabo Group plc
("Kanabo", the "Group" or the "Company")
Directorate Change
Kanabo Group plc (LSE: KNB), a leading patient-focused healthtech ecosystem and provider of personalised medicinal treatments, announces that Dan Poulter has stepped down as Non-Executive Director ("NED") to focus on existing commitments outside of the business.
Kanabo is at very advanced stages of appointing a new UK-based NED to join the Board of Directors, and a further announcement about this will be made imminently.
David Tsur, Chairman of Kanabo, commented:
"I would like to thank Dan for his contribution to the Company. He has been a pleasure to work with and we wish him every success in the future."
Enquiries:
Kanabo Group plc via Vigo Consulting Avihu Tamir, Chief Executive Officer +44 (0)20 7390 0230 Assaf Vardimon, Chief Financial Officer Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker/ Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930 Vigo Consulting (Financial Public Relations/Investor Relations) Jeremy Garcia / Fiona Hetherington / Verity Snow +44 (0)20 7390 kanabo@vigoconsulting.com 0230
About Kanabo Group Plc
Founded in 2017, Kanabo Group Plc (LSE:KNB) is a patient-first HealthTech ecosystem, focused on delivering high quality and innovative medical treatments, via its leading-edge technology platform and disruptive product offering.
The Company is a world leader in the research, development and commercialization of regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Patient care is delivered via the company's NHS-approved online telehealth platform offering video consultations, online prescriptions and access to primary care services. In January 2023, the Company successfully combined its technological and product expertise to launch the Beta phase of its medical cannabis business, initially for chronic pain management, under the new Treat-It brand.
Kanabo Group is committed to evolving more accessible healthcare experiences for every patient.
Visit www.kanabogroup.com for more info.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAFLFVVVIILVIV
(END) Dow Jones Newswires
March 31, 2023 09:40 ET (13:40 GMT)
1 Year Spinnaker Opportunities Chart |
1 Month Spinnaker Opportunities Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
